Safety and Efficacy of Low-Dose Intravenous Immune Globulin (IVIG) Treatment for Infants and Children with Immune Thrombocytopenic Purpura

Purpose: This report presents pooled data from two multicenter studies conducted to assess the efficacy, safety, and tolerance of lower-dose intravenous immune globulin (IVIG) regimens of 250 mg/kg/day, 400 mg/kg/day, and 500 mg/kg/day for 2 days, compared to an established higher-dose regimen of 1